



Drug Formulary Update, October 2019 Commercial

Updates to the HealthPartners Commercial Formularies (PreferredRx and GenericsAdvantageRx) are listed below.

Please see www.healthpartners.com/formularies for details.

All updates are effective October 1.

Members currently receiving these medications are given additional time (through November 30), to work with their provider to update their medication or to submit a prior authorization request.

Drug name	Current Status	New Status	Effective Date	Comments
Abatacept (Orencia)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Abiraterone (Yonsa)	NF-PA, SP Oncology	NF-PA TD, SP Oncology	10/1/2019	Adding to the Trial Drug Program.
Abiraterone (Zytiga Brand)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Abiraterone (Zytiga generic) 250mg	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Acalabrutinib (Calquence)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Adalimumab (Humira)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Afatinib (Gilotrif)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Alectinib (Alecensa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Alosetron (Lotronex)	NF PA	NF PA	10/1/2019	Update PA criteria.
Alpelisib (Piqray)		NF-PA-QL, SP	10/1/2019	A new FDA approval.
Amifampridine (Firdapse)	F-PA-QL, SP	NF-PA-QL, SP	10/1/2019	Remove from formulary, and update PA criteria.
Amifampridine (Ruzurgi)		F-PA-QL, SP	10/1/2019	A new FDA approval.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Apremilast (Otezla)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Axitinib (Inlyta)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Bexarotene (Targretin Brand and generic)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Binimetinib (Mektovi)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Brigatinib (Alunbrig)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Bupropion XL (Wellbutrin XL)	NF-PA	NF-PA	10/1/2019	Update PA criteria.
Cabozantinib (Cabometyx)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Cabozantinib (Cometriq)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Camrese (Seasonique generic)	NF PA	F	10/1/2019	
Camrese Lo (Lo Seasonique generic)	NF PA	F	10/1/2019	
Canakinumab (Ilaris)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ceritinib (Zykadia)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Certolizumab (Cimzia)	F-PA-QL, SP	F-PA-QL, SP	10/1/2019	Updating QL, to FDA-maximum dosing.
Chlorzoxazone (Lorzone)	NF AE	NC	10/1/2019	
Cladribine (Mavenclad)		F SP PA	10/1/2019	A new FDA approval.
Clindamycin/ BPO 1.2-5%	NF PA	NF	10/1/2019	
Clobazam (Sympazan)		NF	10/1/2019	A new FDA approval.
Cobimetinib (Cotellic)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Crizotinib (Xalkori)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dabrafenib (Tafinlar)	F-PA TD, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Dacomitinib (Vizimpro)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dalfampridine (Ampyra Brand)	NF-PA, SP	NF-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dalfampridine (Ampyra generic)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Dexcom continuous glucose monitoring system	Covered	Covered PA	10/1/2019	Adding PA criteria, reserving for those at a higher risk of hypoglycemia including those on short-acting insulin or a sulfonylurea.
Dolutegravir/lamivudine (Dovato)		NF	10/1/2019	A new FDA approval.
Duvelisib (Copiktra)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Enasidenib (Idhifa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Encorafenib (Braftovi)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Erdafitinib (Balversa)		NF-PA, SP Oncology	10/1/2019	A new FDA approval.
Erlotinib (Tarceva generic)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Erlotinib (Tarceva)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Etanercept (Enbrel)	F-PA, SP	F-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Everolimus (Afinitor)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Filgrastim (Granix)	F, SP Oncology	F, SP	10/1/2019	Removing from Oncology Program.
Filgrastim (Neupogen)	F, SP	NF-PA, SP	10/1/2019	Removing from formulary, and adding PA criteria.
Filgrastim (Zarxio)	F, SP	NF-PA, SP	10/1/2019	Removing from formulary, and adding PA criteria.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Freestyle Libre continuous glucose monitoring system	Covered	Covered PA	10/1/2019	Adding PA criteria, reserving for those at a higher risk of hypoglycemia including those on short-acting insulin or a sulfonylurea.
Galcanezumab (Emgality) 100mg/ mL		F-PA-QL, SP	10/1/2019	A new strength.
Gefitinib (Iressa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Gilteritinib (Xospata)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Glasdegib (Daurismo)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Golimumab (Simponi)	NF-PA, SP	NF-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ibrutinib (Imbruvica)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Idelalisib (Zydelig)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Insulin (Relion)	NF	F	10/1/2019	Relion insulin has been added to formulary.
Interferon beta 1b (Extavia)	NF-PA-QL, SP	NF-PA-QL, SP	10/1/2019	Updating quantity limit.
Ivosidenib (Tibsovo)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ixazomib (Ninlaro)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ixekizumab (Taltz)	NF-PA, SP	NF-PA-QL, SP	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Lapatinib (Tykerb)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Larotrectinib (Vitrakvi)	F-PA-QL, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding to the Trial Drug Program.
Lenalidomide (Revlimid)	F, SP Oncology	F-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Lenvatinib (Lenvima)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Lorlatinib (Lorbrena)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Mepolizumab (Nucala)		F-PA, SP	10/1/2019	A new self-administered dosage form.
Milnacipran (Savella)	F ST	F PA	10/1/2019	The new PA criteria are similar to the previous step-therapy criteria.
Neratinib (Nerlynx)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Niraparib (Zejula)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Omacetaxine (Synribo)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Osimertinib (Tagrisso)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Panobinostat (Farydak)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Pazopanib (Votrient)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Penciclovir (Denavir)	NF	Not Covered	10/1/2019	
Pomalidomide (Pomalyst)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ponatinib (Iclusig)	F-PA, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Povidone/hyaluronate/glycyrrhetic acid (Gelclair) gel	NF	Not Covered	10/1/2019	
Procarbazine (Matulane)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Riociguat (Adempas)	F-PA, SP	F-PA, SP	10/1/2019	Update PA criteria.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program

Drug name	Current Status	New Status	Effective Date	Comments
Risankizumab (Skyrizi)		F-PA, SP	7/25/2019	A new FDA approval, previously added to formulary.
Rucaparib (Rubraca)	NF-PA TD, SP Oncology	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Ruxolitinib (Jakafi)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Salicylic acid 6% gel	NF	Not Covered	10/1/2019	
Siponimod (Mayzent)		F SP QL	10/1/2019	A new FDA approval.
Sonidegib (Odomzo)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Sorafenib (Nexavar)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Stiripentol (Diacomit)		F-PA-QL, SP	10/1/2019	A new FDA approval
Sunitinib (Sutent)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Tafamidis (Vyndaqel)		F SP PA	10/1/2019	A new FDA approval
Talazoparib (Talzenna)	NF-PA, SP Oncology QL	NF-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing, and adding to the Trial Drug program.
Telmisartan	NF	F	10/1/2019	
Tezacaftor/ ivacaftor (Symdeko)	F-PA, SP	F-PA, SP	10/1/2019	Update PA
Trametinib (Mekinist)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Trifluridine/ tipiracil (Lonsurf)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vandetanib (Caprelsa)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vemurafenib (Zelboraf)	F-PA, SP Oncology	F-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Venetoclax (Venclexta)	NF-PA, SP Oncology	NF-PA-QL, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vismodegib (Erivedge)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.
Vorinostat (Zolinza)	F-PA TD, SP Oncology	F-PA-QL TD, SP Oncology	10/1/2019	Adding a quantity limit, per FDA-maximum dosing.

Formulary Abbreviations: F = Formulary, NF = Non-Formulary, PA = Prior Authorization, ST = Step Therapy, QL = Quantity Limit, AE = Age Edit, NC = Not covered, SP = Specialty Drug, Oncology = Oncology program, TD = Trial Drug Program